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The effectiveness and design of informed choice tools for people with severe mental 
illness: a systematic review 
Abstract 
Background: People with severe mental illness (SMI) report difficulty in making health- 
related decisions. Informed choice tools are designed to guide individuals through a 
decision-making process.  
Aims: To determine the effectiveness of these tools for people with SMI and to identify what 
methods and processes may contribute to effectiveness. 
Method: A systematic electronic search was conducted for studies published between 1996 
and January 2018. The search was updated in March 2020. Studies of any design reporting the 
development or evaluation of any informed choice tool for people with SMI were considered. 
A structured, narrative synthesis was conducted. 
Results: Ten articles describing four tools were identified. Tools were designed to assist with 
decision-making around bipolar treatment, smoking cessation and disclosure of mental illness 
in employment situations. Positive changes in decisional conflict, stage of change, knowledge 
and self-efficacy were reported for two tools, though insufficient data exists for definitive 
conclusions of effectiveness. Feedback from service users and attention to readability appeared 
key.  
Conclusions: The evidence base for informed choice tools for people with SMI is limited. Such 
tools should be developed in stages and include the views of people with SMI at each phase; 
readability should be considered, and a theoretical framework should be used to facilitate 







In healthcare, there has been a gradual shift from the paternalistic model, whereby the clinician 
holds the power, towards greater patient autonomy and control (Barry & Edgman-Levitan, 
2012; Kaba & Sooriakumaran, 2007). In several countries, including Australia, Canada, New 
Zealand, the US and UK, promoting choice has been regarded as significant to modernising 
health and social care services and has formed part of governments’ delivery plans (Coulter, 
2010), such as Creating a Patient Led NHS in the UK (Department of Health/NHS, 2005) and 
the evolution of Standard Two - Partnering with Consumers within the National Safety and 
Quality Health Services Standards in Australia (Trevena et al., 2017). In mental health services 
in the UK, this includes providing informed choice of service or treatment and care pathway 
(Samele, Lawton-Smith, Warner, & Mariathasan, 2007). There is a shift towards providing 
information to the individual in a way that helps them make an informed ‘choice’, rather than 
simply obtaining informed consent, which is more passive (Coulter, Edwards, Elwyn, & 
Thomson, 2011 ; King & Moulton, 2006; Liu, Burston, Stewart, & Mulligan, 2018; Woolf et 
al., 2005). Informed choice is central to supporting patient autonomy by ensuring that people 
make choices in line with their interests, values and preferences and based on all relevant 
information, as well as being free from coercion (Jepson, Hewison, Thompson, & Weller, 
2005; Smith et al., 2010).  
 
To make an informed choice, information must be understood and presented in a balanced way 
so as not to suggest a right or wrong option (Hope, 2002; Jepson et al, 2005). Uncertainty about 
which course of action to take when choice among competing options involves risk, regret, 
loss, or challenge to personal life values is termed ‘decisional conflict’ (Leblanc, Kenny, 
O’Connor, & Légaré, 2009). ‘Shared decision-making’ interventions are available to support 
individuals’ decisions (Elwyn et al., 2012; Légaré et al., 2018). These may be regarded as an 
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intermediate model between a paternalistic approach and the informed choice model (Charles 
et al., 1997; Kon, 2010) as they facilitate a collaborative process through which a clinician 
supports a patient to reach a decision about their treatment (Elwyn et al., 2010). Shared 
decision-making interventions share similarities with informed choice tools in that they both 
seek to clarify values, but the decision-making process is different as the decision is shared 
with a health professional (Drake et al., 2009; Duncan et al., 2010; Elwyn et al., 2010).  
 
People living with SMI commonly report poor continuity of care (Biringer, Hartveit, Sundfør, 
Ruud, & Borg, 2017) and difficult relationships with health professionals, particularly in 
primary care (Clifton et al., 2016; Ross et al., 2015), so shared decision-making tools may not 
be appropriate for everyone within this population. In addition, primary care clinicians face 
time constraints to using a shared decision-making tool (Gravel et al., 2006), so an informed 
choice tool may be a more suitable format.  
 
Informed choice tools, also known as ‘decision aids’ or ‘decision support tools’, are used to 
guide individuals through a decision-making process and aim to reduce decisional conflict by 
providing the individual with the required information to allow them to make an informed 
choice, while also including their values in the decision-making process (Barratt, 2008). These 
tools, including pamphlets, web-based tools or videos, describe the decision to be made and 
the options available, and help people to think about the options from a personal viewpoint 
(Stacey et al., 2017). They may include ‘personal stories’, testimonies or videos of people who 
have faced a similar decision.   
 
In the general population, informed choice tools have been shown to be effective in helping 
people make decisions about a range of health issues (Stacey et al., 2017). Such tools may be 
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beneficial for people with SMI, however, a proportion of this population may have difficulty 
in processing health information (Borzekowski et al., 2009; Castillo, Rosati, Williams, Pessin, 
& Lindy, 2015; Clausen, Watanabe-Galloway, Baerentzen, & Britigan, 2016; Ferron et al., 
2011; Stahl, 2003) which may impact on how informed choice tools are used by them 
(Borzekowski et al., 2009; Clausen et al., 2016; Ferron et al., 2011). The optimal design for an 
informed choice tool for people with SMI is unknown. This study addresses this by 
systematically reviewing the literature to answer the following questions: (1) how effective are 
informed choice tools for people with SMI in improving decision making outcomes and (2) 
what methods and processes contribute to the effectiveness of informed choice tools for people 
with SMI.  
Methods 
This systematic review is reported in accordance with the 2009 PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) statement (Moher et al., 2009). The review 
protocol is registered on the International prospective register of systematic 
reviews(PROSPERO Registration number anonymised for peer review).   
 
Searches 
Electronic searches of Cochrane Central Register of Controlled Trials, EBSCOhost, Web of 
Science, Academic Search Elite, MEDLINE, EMBASE, CINAHL and PsycINFO were 
conducted (as part of a PhD) in March 2018 for studies published since 1996. The search was 
updated in March 2020 and an additional study was identified for inclusion (Fisher, Sharpe, 
Anderson, Manicavasagar, & Juraskova, 2018). Grey literature, i.e. conference abstracts 
through Open Grey and the Grey Literature Report, was searched and reference lists of included 
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studies and relevant review articles were reviewed. Searches were restricted to English 
language publications. The first author of the included studies was contacted by one reviewer 
(FLG) to find relevant unpublished work. The search strategy, which was adapted from related 
systematic reviews (Colquhoun, Squires, Kolehmainen, Fraser, & Grimshaw, 2017; Taylor et 
al., 2017) and checked by a specialist health librarian, included relevant synonyms and search 
tools to ensure maximum sensitivity. The full list of search terms has been published 
(Lamontagne-Godwin et al., 2017); this and a full electronic search strategy for one database 
(MEDLINE) is available as an additional file.  
Inclusion and exclusion criteria 
We included studies of any design describing the development or evaluation of any informed 
choice tool targeted specifically for use by adults with SMI, where the aim of the tool was to 
improve decision making outcomes. Studies of shared decision-making tools which could not 
be used by people with SMI without input from a healthcare professional were excluded.  
 
For this review, SMI was defined using the ICD-10 (World Health Organisation, 1992, updated 
2016) codes as schizophrenia spectrum disorders (F20.0-F20.9), schizoaffective disorders 
(F25), bipolar affective disorder (F31) and recurrent depressive disorder with psychotic 
symptoms (F33.3). We included studies where participants were defined by authors as having 
SMI even when specific diagnoses were not provided (Ferron et al., 2011; Ferron et al., 2016; 
Brunette et al., 2017). Study participants had to be adults (18 years or over) of any gender with 
an SMI, however diagnosed, and treated in any setting. Studies of participants with severe 
depression without psychotic symptoms were excluded from this review as there is evidence 
that their behaviour around screening decision-making differs from that of people with 




Study participants with co-morbid physical illness were eligible. Participants with co-morbid 
substance abuse disorders were eligible only if they were engaged in treatment for these 
conditions. Studies with populations involving people with mental disorders other than those 
defined as severe above (e.g. obsessive compulsive or anxiety disorders) were included only if 
more than 50% of participants had a diagnosis of SMI, or if data limited to those with SMI 
were available. Studies not published in English were excluded due to lack of resources for 
translation.   
 
Study selection 
Titles and abstracts were screened independently by one reviewer (FLG) to identify potentially 
eligible studies. A random sample (10% of the titles and abstracts) was collected by FLG from 
the total list of abstracts using the Excel RANDBETWEEN function; this sample was sent to 
the second reviewer (RS) for screening. The second reviewer (RS) was selected for this task 
because of their different academic background; the aim being to minimise possible discipline-
related bias. 
Agreement between the two reviewers was 80%; differences were reconciled with a third (EB) 
and fourth reviewer (CL) through discussion. Cohen’s kappa could not be computed due to 
reviewer one (FLG) having rejected all the titles from the sub-sample reviewed by the second 
reviewer (RS). The full text of potentially eligible studies was assessed for inclusion by three 
reviewers (FLG, CL and RS). Disagreements (n = 4) were resolved through discussion between 




The quality of the included studies was assessed using ‘ICROMS’ (Integrated quality Criteria 
for the Review Of Multiple Study designs) (Zingg et al., 2016). This allows reviewers to 
attribute points to studies for a range of quality criteria, which are assessed using seven 
dimensions (e.g. managing bias in outcome measurements and blinding, managing bias in 
sampling or between groups). Scores for each criterion are: Yes (criterion met): 2 points; 
Unclear: 1 point; No: 0 points. The sum of points attributed to each criterion represents the 
global quality score for a study. Studies were not excluded based on quality, but assessments 
of quality informed the data synthesis and interpretation of results. Three reviewers 
independently assessed study quality (FLG, CL and RS); discrepancies were resolved through 
discussion. 
Data extraction  
Data extraction forms were piloted and used by one author (FLG) to develop a data extraction 
framework, which was then reviewed by two authors (CH and EB). Papers were divided into 
two categories: 1) those describing the evaluation of a tool (Table 1) and 2) those describing 
the development of the tool (Table 2). Some papers described both. Data were extracted and 
synthesised from Table 1 [demographics and setting of participants, intervention evaluation 
(design, outcomes, results), and main study weaknesses] and Table 2 [demographics and setting 
of participants, response rate, sample size, methods (tool development, description of tool, use 
of behaviour change theory) and study weaknesses]. One author (FLG) extracted all the data; 
a second author (CL) verified half the extracted data while a third author (RS) verified the other 
half. 
Data synthesis  
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A narrative synthesis of the effectiveness findings from the included studies was produced 
(Popay et al., 2006). Data from all outcomes reported in the selected studies were included in 
our synthesis. To assess effectiveness, we considered decisional conflict and knowledge to be 
primary outcomes, as these are key indicators of improvement in decision-making (Stacey et 
al., 2017). Meta-analysis was not possible due to insufficient data, heterogeneity in study 
design and outcome measures used. To identify what methods and processes may contribute to 
effectiveness, extracted data were reviewed to identify common and key steps used across 
studies to develop the tools. Steps were agreed through discussion by the entire team.  
[Tables 1 and 2 near here]  
Results  
Search results are summarised in the PRISMA flow chart (Moher, Liberati, Tetzlaff, Altman, 
& The PRISMA Group, 2009) (figure 1). Ten studies (Australia: n = 1, Germany: n = 1, 
England: n = 2 and United States: n = 6) were included. These described four tools:  a decision 
aid to assist people with SMI to decisions regarding disclosure of their mental health status in 
the employment context, termed here ‘disclosure tool’ (Brohan et al., 2014a; Henderson et al., 
2013); 2) a web-based decision support system to stimulate motivation in people with SMI to 
quit smoking, termed ‘smoking cessation tool’ (Brunette et al., 2011; Brunette et al., 2013; 
Brunette et al., 2017; Ferron et al., 2011; Ferron et al., 2012; Ferron et al., 2016); 3) a web-
based decision aid to encourage patients to participate in decision-making about treatment 
options for bipolar disorder termed ‘treatment choice tool’; this tool has not been evaluated 
(Liebherz et al., 2015); 4) a decision aid (booklet) for people with bipolar II disorder and their 
families making decisions about treatment options to prevent relapse, termed ‘relapse 
prevention tool’; a feasibility study protocol has been published (Fisher et al., 2018; Fisher et 
al., 2018b). A description of the tools can be found in Tables 1 and 2. 
[Figure 1 near here] 
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Quality of included studies 
Two studies describing the development of the tools did not clearly fit any design category 
within the ICROMS framework.  The treatment choice tool (Liebherz et al., 2015) reported 
participant responses to an unvalidated survey, whilst the relapse prevention tool (Fisher et al., 
2018) used a cross sectional mixed design to assess the tool’s acceptability, feasibility, safety 
and usefulness. Three studies did not meet the minimum quality score attributed to their study 
design: 15.5/22 (Ferron et al., 2011), 21/22 (Brohan et al., 2014a) and 20.5/22 (Ferron et al., 
2012). The quality of these three descriptive studies could only partially be assessed as their 
study designs lacked an exact fit with the ICROMS framework. One study (Ferron et al., 2016) 
met the minimum quality score and five scored above it (Brunette et al., 2011; 2013; 2017; 
Henderson et al., 2013; Liebherz et al., 2015). The main study weaknesses are described in 
Tables 1 and 2, small sample size and lack of generalizability were common. Overall, the 
quality of evidence for developmental studies was rated moderate and the quality of evidence 
for the evaluation studies was rated good.  
 
Evidence of effectiveness 
No effectiveness data are available for the treatment choice (Liebherz et al., 2015) and relapse 
prevention (Fisher et al., 2018) tools. The disclosure tool was evaluated in a pilot and in an 
exploratory randomised controlled trial (RCT) (Brohan et al., 2014a; Henderson et al., 2013). 
The smoking cessation tool was evaluated in a pilot study (using a quasi-experimental design) 
(Brunette et al., 2011), an RCT (Brunette et al., 2013), using secondary analysis of data (Ferron 
et al., 2012) from the RCT (Brunette et al., 2013), at 6-month follow-up of the RCT (Ferron et 
al., 2016) and in a randomised, controlled pilot study comparing the smoking cessation tool to 
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the computerised smoking education tool from the American National Cancer Institute (ANCI) 
(Brunette et al., 2017). Reported outcomes are included in Table 1 and summarised below. 
Primary outcomes  
Decisional conflict 
This was measured using the validated Decisional Conflict Scale (O’Connor, 1993, updated 
2010) in a before and after study (n = 15) and an RCT (n = 79) of the disclosure tool (Brohan 
et al., 2014a; Henderson et al., 2013). Both studies met criteria necessary to achieve the 
minimum quality score. A reduction in decisional conflict associated with use of the tool was 
seen in all groups (Brohan et al., 2014a; Henderson et al., 2013); a significant difference in 
favour of the intervention group compared with a usual care control group was found at three-
month post use (Henderson et al., 2013) (Table 1).  
 
Knowledge 
This was measured in one study (n = 58) (Brunette et al., 2013), the primary aim of which 
was to test the effect of carbon monoxide feedback as an additional component to the 
smoking cessation tool. This study met minimum quality criteria. At two-month follow-up, 
intervention group participants reported to research interviewers (type of interview not 
specified) increased knowledge about the risks of carbon monoxide compared to the control 
group; the difference was statistically significant. However, there was no difference in 
rudimentary knowledge about the health consequences of smoking between groups (Table 1).  
 
Other outcomes reported 
Stage of change (i.e. the participant’s perceived degree of readiness to change their behaviour): 
This was measured in five studies (Brohan et al., 2014a; Brunette et al., 2013; Ferron et al., 
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2012; Ferron et al., 2016; Henderson et al., 2013); a range of measures was employed. The 
Stage of Decision Making scale (1-5) (O’Connor, 2000, updated 2003) was used for the 
disclosure tool (Brohan et al., 2014a; Henderson et al., 2013). The impact of the disclosure tool 
on the individual’s readiness to engage in decision-making was tested in two studies (Brohan 
et al., 2014a; Henderson et al., 2013) (n = 15 and 79 respectively). No statistically significant 
change was found in any analysis, though improvement was indicated in one group pre and 
post completion of the tool (Brohan et al., 2014a) and between immediate and three-month 
follow-up in another (Henderson et al., 2013). The impact of the smoking cessation tool on the 
stage of change was tested in three studies (n = 124, 135 and 124 respectively) (Brunette et al., 
2013; Ferron et al., 2012; Ferron et al., 2016) by asking “Are you seriously thinking about 
quitting?” responses were scored using a four-point scale (DiClemente et al., 1991; Donovan, 
Jones, Holman, & Corti, 1998). Two studies (Brunette et al., 2013; Ferron et al., 2012) did not 
report their findings for this outcome; in the third study (Ferron et al., 2016) improvement was 
indicated pre and post use of the tool (Table 1).  
Empowerment: This was measured in one study (Henderson et al., 2013) using two subscales 
of the Boston University Empowerment Scale (Rogers, Ralph, & Salzer, 2010): Factor 1 (Self-
esteem–self-efficacy) and Factor 2 (Power–powerlessness). Statistically significant 
improvement was found in favour of those using the disclosure tool compared to usual care on 
the Factor 2 subscale, but there was no difference between groups in terms of self-esteem 
[Table 1].  
 
Attitudes and beliefs  
A range of attitudes and beliefs was measured using different tools; some studies adapted 




Behavioural withdrawal: This was measured in one study of the disclosure tool (Henderson et 
al. 2013) using an adapted measure. No significant difference between groups was found at 
any time point.  
 
Behavioural motivation: Four studies assessed whether the smoking cessation tool had any 
impact on behaviours indicative of motivation to quit smoking (Brunette et al., 2011; Brunette 
et al., 2013; Ferron et al., 2012; Ferron et al., 2016), though one study (Ferron et al., 2016) is a 
secondary analysis of data from a parent study (Brunette et al., 2013), so these data were 
reported twice. All used the Behavioural Motivation Index (Brunette et al., 2011).  
 
Importance of quitting smoking: In one study (Brunette et al., 2017) the primary outcome 
selected was the proportion of participants who, following use of a smoking cessation 
intervention (either the smoking cessation tool or the ANCI tool), were using verifiable 
cessation treatment at the three-month follow-up. This outcome was reported for 6% of 
participants (no breakdown was given by intervention). Following use of either intervention, 
participants rated the importance of quitting highly (mean 5.7 ± 1.4 on a 1–7 scale) however 
intentions to use cessation treatments were relatively low (mean 3.6 ± 1.9 on a 1–7 scale) 
(Brunette et al., 2017). Authors reported there was no difference between intervention groups 
in intentions and importance of quitting. 
 
Smoking behaviours: two months after use of the smoking cessation tool, over half (52.9%) of 
participants in one study (Brunette et al., 2013) reported having engaged in at least one 
cessation behaviour; this increased to 55.6% at 6 months when and nearly 40% had also 




Verifiable smoking cessation treatment was tested in three evaluations of the smoking cessation 
tool (Brunette et al., 2013; Brunette et al., 2017; Ferron et al., 2012). In two studies, one a RCT 
(Brunette et al., 2013), the other a non-controlled interrupted time series (Ferron et al., 2012), 
use of the tool was associated with smoking cessation behaviour (51% of participants in the 
Ferron et al. 2012 study). Approximately 30% of the group initiated a cessation treatment by 
discussing treatment options with a smoking cessation specialist; a third evaluation 
(randomized pilot study) reported about 6% over the three-month follow-up period (Brunette 
et al., 2017). Authors reported that the reason behind the participants’ change in smoking 
behaviour could be due to the flexible design of the smoking cessation tool, which might allow 
participants to tailor their use of the tool to meet their individual needs (Ferron et al., 2012). 
 
Self-reported abstinence from smoking was tested in two studies which met the minimum 
quality criteria (Brunette et al., 2017; Ferron et al., 2016). Ferron et al. (2016) reported that 
overall, the smoking cessation tool engaged most participants into cessation activity: 60 % of 
participants (N = 74) abstained from smoking for at least one day over the six-month follow-
up period. Sustained abstinence was recorded for 29% of participants for at least seven days, 
while 7% persisted in their abstinence at six-month follow-up (Ferron et al., 2016). Another 
evaluation assessed whether the rate of treatment initiation and cessation behaviours would be 
higher among users of the tool in comparison to users of the computerised American National 
Cancer Institute (ANCI) education tool on smoking cessation (Brunette et al., 2017). No 
participant from the ANCI group achieved verified abstinence, while almost 15% of 
participants who used the smoking cessation tool met the study’s definition of biologically 
verified abstinence at the 14-week follow up (Brunette et al., 2017). 
Development and design of informed choice tools  
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Four studies involving participants living with SMI (smoking cessation: n = 71, disclosure: n 
= 15, treatment choice: n = 210, relapse prevention: n =31 as well as n = 11 family members) 
described the informed choice tools’ development (Brohan et al., 2014a; Ferron et al., 2011; 
Fisher et al., 2018; Liebherz et al., 2015); data are summarised in Table 2 and synthesised 
below.  
 
Step One: Identify barriers to decision-making 
The disclosure (Brohan et al., 2014a) and treatment choice (Liebherz et al., 2015) tools were 
informed by an initial systematic review of barriers to decision-making (Brohan et al., 2012; 
Tlach et al., 2014). The smoking cessation tool was informed by a review of smoking cessation 
interventions for adults with SMI which identified barriers to that behaviour (Ferron, Alterman, 
McHugo, Brunette, & Drake, 2009). The disclosure tool was informed by a primary qualitative 
study to explore people’s experience of disclosure of their mental health problems (Brohan et 
al., 2014b). Authors of the relapse prevention tool (Fisher et al., 2018) systematically reviewed 
studies of communication and decision-making in mental health-based samples including 
patients with bipolar disorder (Fisher, Manicavasagar, Kiln, & Juraskova, 2016). 
 
Step Two: Theoretically underpin the intervention  
The disclosure and smoking cessation tools used the Theory of Planned Behaviour (Ajzen, 
1991) to inform content development (Brohan et al., 2014a; Ferron et al., 2011). The disclosure, 
smoking cessation and relapse prevention tools (Brohan et al., 2014a; Ferron et al., 2011; Fisher 
et al., 2018) used the Ottawa decision support framework (O’Connor, 1999). Use of these 
frameworks ensured that the tools were theoretically underpinned (Moore et al., 2015). The 
theoretical basis for the disclosure tool (Brohan et al., 2014a) was an integrated disclosure 
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framework developed from a systematic review (Brohan et al., 2012) and qualitative work 
(Brohan et al., 2014b).  
 
Step Three: Service user-led content development  
People with SMI were involved in the development of each tool in different ways. Feedback 
from people with SMI was collected using semi-structured interviews during the development 
of the smoking cessation, relapse prevention and disclosure tools (Brohan et al., 2014a; Ferron 
et al., 2011; Fisher et al., 2018). Questions focused on their general opinions on the tool, other 
information/experiences which they felt should be included and any amendments to existing 
information (Brohan et al., 2014a). For the relapse prevention tool, participants were asked to 
read the tool and then complete validated and purpose-designed questionnaires. A follow-up 
semi-structured telephone interview elicited additional feedback on the tool (Fisher et al., 
2018). Feedback was collected for the treatment choice tool using an online cross-sectional 
survey (Liebherz et al., 2015). The think-aloud method was also used by authors of the 
disclosure tool (Brohan et al., 2014a). Think-aloud observations are a validated method to 
assess user experience and usability of interventions and allows observation of the actual 
reactions of the participant using the tool (McDonald, Zhao, & Edwards, 2016; van Someren, 
Barnard, & Sandberg, 1994). The method has been used successfully to test a smoking 
cessation app with participants who have SMI (Vilardaga et al., 2016). 
Step Four: Ensure ease of use  
Ease of use was tested in three studies of the smoking cessation tool (Brunette et al., 2017; 
Ferron et al., 2011; Ferron et al., 2012), one study of the relapse prevention tool (Fisher et al., 
2018) and one study of the disclosure tool (Brohan et al., 2014a). The Perceived Usefulness 
and Ease of Use Scale (Davis, 1989) was adapted and used in an evaluation of the smoking 
cessation tool to assess participants’ perceptions of the usefulness and ease of operating the 
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tool. Authors of the relapse prevention tool assessed participant feedback using an adapted 
measure from previous acceptability studies of mental health decision-support tools (Tlach et 
al., 2016). Participants reported their agreement with the tool’s perceived ease of use (8 items), 
perceived usefulness (9 items), attitudes towards using (3 items), and perceived bias (4 items).  
 
Most participants testing the smoking cessation tool (n = 124) reported high levels of 
satisfaction with the first and second (revised) version of the tool as well as the presentation of 
the information (Ferron et al., 2012). Results showed an increased ease of use from the first to 
the last version of the website, which was reflected in participants’ reduction in unproductive 
clicking and with fewer questions asked about how to use the tool (Ferron et al., 2011). An 
evaluation study of the smoking cessation tool compared it with the computerised ANCI tool 
(Brunette et al., 2017). Users took part in a semi-qualitative interview (an adapted version of 
the Perceived Usefulness and Ease of Use Scale) and described how although they felt that 
both the tool and the ANCI tool were “easy to use,” 10.7% of ANCI education users versus 
3.3% of users of the smoking cessation tool felt it was “hard to understand”. In terms of 
satisfaction, 71.4% of the ANCI education users and 83.4% of users of the tool described the 
intervention as “good” or “very good”.  
 
For the smoking cessation intervention, suggested improvements included integrating a mouse 
tutorial, using a flat interface, increasing font and button sizes, using a blank background with 
a simple border graphic and using text to speech software. To ensure usability of the smoking 
cessation tool, authors consulted previous research on usability for people with schizophrenia 
(Rotondi et al., 2007) and applied usability guidelines for people with cognitive deficits (United 




Overall, participants (n = 31 patients and n = 11 family members) testing the relapse prevention 
tool reported it as easy-to-use and useful in treatment decision-making, presenting balanced, 
up-to-date and trustworthy information that did not provoke anxiety. Participants (n = 15) 
testing the disclosure tool rated its relevance highly as well as speed and ease of use (Brohan 
et al., 2014a).  
 
Step Five: Ensure readability 
 
The reading capability level of participants with SMI was checked during the development 
phase of the disclosure and smoking cessation tools (Brohan et al., 2014a; Ferron et al., 2011). 
Authors of the disclosure tool refer to the Flesch-Kincaid (Flesch Reading Ease and the Flesch–
Kincaid Grade Level) readability tests, while authors of the smoking cessation tool used the 
US-based web design and usability guidelines (United States Department of Human Services, 
2010). Following feedback from participants, interventionists developing the tools revised the 
readability of their tools to a revised Flesch-Kincaid Grade level of 8.4 i.e. to be understandable 
by the average US 8th - 9th grader (aged 13-15 years) and from an 8th grade to below 5th grade 
reading level respectively (Brohan et al., 2014a; Ferron et al., 2011). Further feedback 
concerning the format and design layout of tools suggested that providing definitions, 
simplifying language, ‘breaking down’ the information and including verbatim quotes or 
videos from their peers is helpful. Authors of the relapse prevention tool did not assess its 
readability levels, as readability was not considered an appropriate index of comprehensibility 
given the complex medical terminology included in the tool (Fisher et al., 2018). Authors 
included this terminology which was felt to be necessary and provided definitions in simple, 
descriptive terms in the tool’s glossary. The tool was professionally copy-edited for low health 
literacy levels. In addition, a health literacy review of the tool was conducted using the Patient 
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Education Materials Assessment Tool (Shoemaker, Wolf, & Brach, 2014). The tool scored as 
an easy to understand and use patient education material. 
 
For online interventions, computer literacy is also important for readability. Computer literacy 
levels were reported for several studies describing the smoking cessation tool: computer use 
(>5 times) for 11 out of 21 participants (52.4%) in the intervention group and 6 out of 20 (30%) 
for the control group (Brunette et al., 2011); computer use (>5 times) for 20 out of 58 
participants (34.5%) of the intervention and carbon monoxide monitor group and 29 out of 66 
participants (44%) of the intervention only group (Brunette et al. 2013); no computer 
experience for 30 out of 131 participants (22%), computer use (<5 times): 23 out of 131 (17%) 
and computer use (>5 times): 82 out of 131 (61%) (Ferron et al., 2012). Brunette et al 
(2017)  reported several computer literacy indicators : being comfortable using a computer : 25 
out of 30 participants (83.3%) in the intervention group, 24 out of 28 participants (85.7%) using 
the ANCI tool and 18 out of 23 participants (78.3%) with no intervention; having their own 
smartphone : 19 out of 30 (67.9%) for the intervention, 23 out of 28 (76.7%) using the ANCI 
tool and 21 out of 28 (91.3%) with no intervention; used the Internet in the past year: 29 out of 
30 (96.7) for the intervention group, 26 out of 28 (92.9%) using the ANCI tool and 23 out of 
23 (100%) for the group with no intervention and lastly use of the Internet to look up health 
information: 14 out of 30 (46.7%) for the intervention group,  21 out of 28 (75%) using the 
ANCI tool and 12 out of 28 (52.2%) with no intervention. The Ferron (2011) study did not 
report data on individual participants ; authors highlighted that many participants lacked 
exposure to computers (such as difficulty using a mouse) and lacked knowledge on how to 
navigate a website and had limited to no experience with the web. The treatment choice tool 
reported on internet use of participants: 195 out of 210 participants (93.3%) used the Internet 
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daily and 104 out of 210 participants (49.5%) used the Internet more often for general health 
information searches, minimum once a week up to daily (Liebherz et al., 2015). 
 
Discussion  
This systematic review identified four available informed choice tools that people with SMI 
can use alone without requiring support from a professional. Due to some small sample sizes 
and heterogeneity between studies, conclusions about the effectiveness of these tools are not 
possible.  Nevertheless, some data exist which suggest that such tools may facilitate a reduction 
in decisional conflict and movement in stage of change towards decision-making. Improved 
knowledge was recorded in small sample sizes; more data are required to assess effectiveness. 
Some decision-specific attitudes improved following the use of a particular tool such as 
increased empowerment (disclosure tool), behavioural motivation, importance of quitting and 
self-reported cessation behaviours (smoking cessation tool), although the validity of measures 
used is uncertain in some cases and data are few so these findings should be interpreted with 
caution.  Step One is important in view of findings that the smoking cessation tool performed 
better than a tool aimed at the general population (the ANCI computerised smoking education 
tool) (Brunette et al., 2017). This was the only study to compare a SMI specific tool with that 
aimed at another population and highlights that there are specific barriers to decision making 
which are related to having an SMI. This has been found in studies of decisions to take up 
cancer screening (Clifton et al., 2016) and other health screening (Lamontagne-Godwin et al., 
2018) by this population. 
The optimal processes for the other identified steps remain unclear however and may vary 




Authors of the smoking cessation, relapse prevention and disclosure tools (Brohan et al., 2014a; 
Ferron et al., 2011; Fisher et al., 2018) sought to increase readability by providing definitions, 
simplifying the language and breaking down the information. Further simplification of the 
disclosure tool may have been required for some users, but it was thought that this could risk 
diluting the complexity of the disclosure decision-making, thus lowering its effectiveness 
(Brohan et al., 2014a). Hence there is a balance between readability and effectiveness for a 
proportion of potential users which researchers developing interventions will have to consider.  
 
This review identified limited use of theoretical frameworks in tool development, as 
recommended by the MRC framework and related guidance (Craig et al., 2008; O'Cathain et 
al. 2019) – only the smoking cessation and disclosure tools were informed by theory. Lack of 
use of theoretical framework in the included studies meant that we were unable to determine 
empirical methods related to optimal effectiveness.  
 
Finally, due to the paucity of available tools and the heterogeneity between them, we were 
unable to determine the best format for informed choice tools for people with SMI, such as 
whether paper- or web-based- tools are more appropriate. We identified two paper-based 
(Brohan et al., 2014a, Fisher et al., 2018) and two web-based tools (Ferron et al., 2011; 
Liebherz et al., 2015), though no study directly compared the two formats (Ferron et al., 2012). 
The authors of the relapse prevention tool (Fisher et al., 2018) have published a protocol for a 
feasibility RCT of  a decision aid website (e-DA) to support young adults with bipolar II 
disorder (BPII), and their families (Fisher et al., 2018b). A systematic review investigating the 
acceptability of mobile phone- and online- delivered interventions for people with SMI (Berry, 
Lobban, Emsley, & Bucci, 2016) advised researchers to use qualitative methods to assess 
acceptability at each phase of intervention development and testing, due to attrition rates in the 
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completion of modules within an intervention. Authors of another systematic review (Batra et 
al., 2017) on the use of digital health technology for patients with SMI concluded that long-
term data are needed to fully understand its usefulness and acceptability for people with SMI 
(Batra et al., 2017).  
 
 
Strengths and limitations of this review 
This is the first systematic review to explore the development and evaluation of informed 
choice tools for people with SMI. Findings inform a list of steps that interventionists can follow 
when developing such tools for this group. The review includes heterogeneous interventions 
from different settings and mental health systems, so findings should be interpreted cautiously 
and the impact of setting considered. The generalizability of our findings may be reduced as 
we applied a narrow definition of severe mental illness (psychosis), which excluded studies 
focusing on other mental health conditions such as anxiety disorders or Post-traumatic stress 
disorder (PTSD). People with these disorders may face different challenges which may not be 
relevant to those diagnosed with psychosis. It is unlikely that any one tool would be suitable 
for a very diverse population. A strength of this review is that ICROMS, a robust framework, 
was used to assess study quality; however a limitation is that it was not fully able to capture 
the design of the descriptive studies. 
 
Implications for research and practice 
Few informed choice tools exist for people with SMI. Preliminary findings suggest these tools 
may facilitate decision-making, though more data are needed to confirm this. This systematic 
review provides a preliminary list of steps for interventionists seeking to develop informed 
choice tools for people with SMI. The development of such tools should proceed in stages and 
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include the views of people with SMI at each phase. Attention should be paid to readability 
and computer literacy, which are heterogeneous within this population and important variables 
to consider when developing an intervention for this group. In addition, emphasis should be 
placed on addressing the different functional impairment needs that can be present for people 
with lived experience of SMI. Use of a theoretical framework would assist in determining how 
interventions may work best to inform adjustments. Future research should establish a solid 
evidence base regarding the effectiveness of informed choice tools for this group before such 
tools can be delivered and scaled up into routine practice. 
Funding: This work was supported by a University [Anonymised] Vice-Chancellor PhD 
Scholarship in Allied Health (2017-2020). The funder had no involvement in the conduct of 
the research and/or preparation of the article. 
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  Table 1. Evaluation Studies 
 
Participants Intervention evaluation Main study weaknesses  Global quality 
score (ICROMS) Demographics Setting Design Outcomes Results 
Intervention: Decision aid for disclosure of mental illness to employers (Brohan et al., 2014a) 
N = 15 (8 female) 
 
Ethnicity: 
White British: N = 8 
Black African: N = 3                             
Black Caribbean: N = 
1                      
Black British: N = 1                                   
Other white 
background:  
N = 1                                    
 
Diagnosis:  
Bipolar disorder: N = 
7 
Schizophrenia: N = 1 









(a) stage of 









brevity, ease of use, 
relevance to self 
and others 
 
To obtain further 






Mean Decisional Conflict Scale scores 
improved after completing the 
informed choice tool  
 
Mean Stage of Decision-making Scale 
score reduced (indicating 
improvement) 
 
Participants found the tool quick to use 
(60%), relevant (60%) and would 
recommend it to others (80%) 
 
80% reported that they would 
definitely or probably use the tool in 
making disclosure decisions 
  
Lack of power to detect 
statistically significant change 
in outcome scores 
 
Small unrepresentative sample 
– limited generalisability  
 










Participants Intervention evaluation Main study 
weaknesses  
Global quality score 
(ICROMS) Demographics Setting Design Outcomes Results 
Intervention: Decision aid for disclosure of mental illness to employers (Henderson et al., 2013) 
N = 79 (control group = 39, 
intervention group = 40) 
Control group (20 female) 
Ethnicity: 
White: N = 16 
Black/Black British: N = 17 
Asian/Asian British: N = 2 
Other: N = 4 
Diagnosis:  
Schizophrenia spectrum: N = 
13 
Bipolar disorder: N = 6 
Mixed: N = 2 
Don’t know: N = 6 
Intervention group (18 
female): 
Ethnicity: 
White: N = 14 
Black/Black British: N = 20 
Asian/Asian British: N = 1 
Other: N = 5 
Schizophrenia spectrum: N = 
11 
Bipolar disorder: N = 7 
Mixed: N = 3 












controlled trial  
 
Participants were 
randomly assigned to use 
of the tool plus usual care 
or usual care alone. 




(a) stage of decision-
making                              
(b) decisional conflict 
(c) employment-related 
outcomes                      
Secondary outcomes:            
(a) eight-item self-
assessment of work 
performance (short 






(17 items) of the original 
Boston University 
Empowerment Scale  
No substantial difference 
between trial arms for any 
variable 
 
No outcome measures were 
associated with loss to 
follow-up 
 





related activity  
29 (minimum score 







Main study weaknesses  Global quality score 
(ICROMS) 
Demographics 
Setting Design Outcomes Results 
 
Intervention: Decision support system to motivate people with SMI to quit smoking [Let’s Talk About Smoking] (Brunette et al., 2011) 
N = 41 (control 
group = 20, 
intervention group = 
21) 
 
Control group (7 
female): 
Ethnicity: 
African American: N 
= 17 
Other: N = 3 
 
Diagnosis: 
Schizophrenia: N = 
19 




African American: N 
= 20 
Other: N = 1 
 
Diagnosis: 
Schizophrenia: N = 9 
























followed up two 
months later to assess 
for behaviours 
indicative of 








participants who had used 
the smoking cessation tool 
were more likely to have 
engaged in at least one 
smoking cessation 
motivation behaviour 
(67%) than those in the 






characteristics of the 
groups 
 
Differing levels of intensity 
of the experimental and 
control interventions            
                                                                          
Authors did not correct for 
the number of statistical 
tests 
24 (minimum score 
required: 18)  




                    
Setting Design Outcomes Results 
Global quality score 
(ICROMS) 
Intervention: Decision support system to motivate people with SMI to quit smoking [Let’s Talk About Smoking] (Ferron et al., 2012) 
N = 135 (38 
female)                                          
 
Ethnicity: 
Black: N = 64 
White: N = 49 
Latino: N = 19                            





disorder: N = 95 
Mood disorder: 
N = 34 










RCT of whether 
use of feedback 
from a carbon 
monoxide 
monitor was a 
necessary 




Primary outcomes:  
(a) process variables, 
including length of time 
spent on two tool 
subsections and choice of 
video host 
(b) behavioural outcome 
variables, including 
number of behaviours 
indicative of motivation 
to quit smoking (e.g. 
evidence-based 
treatment initiation) 
About a third of the group 
initiated cessation 
treatment.  
Almost a third met with a 
smoking cessation 
specialist to discuss 
treatment 
Almost 40% of 
participants discussed 
using a smoking cessation 
medication with their 
doctor.  
More than 50% of the 
participants engaged in 
one or more behavioural 
indicator of motivation 
Monetary compensation 
provided to participants 
($15) may have 
contributed to the high 
feasibility results of the 
tool 
 
The study doesn't allow 
the “host choice” (i.e. 
participant can choose 
gender, ethnicity etc of 
the “online host” of the 
tool) aspect to be 
evaluated (i.e. whether it 
improves efficacy of the 
website) 
20.5 (minimum score 






















Intervention: Decision support system to motivate people with SMI to quit smoking [Let’s Talk About Smoking] (Brunette et al., 2013) 
= 124 (control group = 66, 
intervention group = 58) 
Control group (21 female): 
Ethnicity: 
African American: N = 30 
White: N = 16 
Hispanic: N = 12 
Diagnosis: 
Schizophrenia/schizoaffectiv
e disorders: N = 46 
Bipolar/depressive disorders: 
N = 18 
Intervention group (14 
female): 
Ethnicity: 
African American: N = 30 
White: N = 26 
Hispanic: N = 6 
Diagnosis: 
Schizophrenia/schizoaffectiv
e disorders: N = 38 
Bipolar/depressive disorders: 






controlled trial  
Primary outcome: initiating 
cessation treatment over two 
months    
                                                                                       
Secondary outcomes:  
(a) amount and frequency 
of smoking over the two 
months 
(b) satisfaction with the 
website  
(c) stage of change (four-
point scale, from 'now' 
to not thinking of 
quitting smoking) 
(d) basic knowledge about 
the health effects of 
smoking 
(e) knowledge about 
carbon monoxide 
 
At the two-month follow-
up participants in the 
carbon monoxide group 
increased their knowledge 
about carbon monoxide 
 
Basic knowledge about the 
health effects of smoking 




The main and secondary 




Overall, 32% of 
participants initiated 
treatment. The main 
outcome, initiating 
cessation medication or 
counselling, did not differ 
between groups  
Study did not evaluate 
whether smokers with 
a particular diagnosis 
were more or less 
likely to respond to the 
intervention.  
Study did not include a 
placebo or an attention 
control condition. 
 
Purpose of study was 
to demonstrate the 
impact of the tool on 
treatment use, so there 
was no comparison 
group to document the 
rate of treatment 
initiation and 
abstinence in people 
who did not receive the 
tool.  
Self-reported rate of 




required: 22)  









Intervention: Decision support system to motivate people with SMI to quit smoking [Let’s Talk About Smoking] (Ferron et al., 2016) 
N = 124 (35 female) 
 
Ethnicity: 
African American: N = 57 
White (non-Hispanic): N = 37 
Hispanic: N = 18 
 
Diagnosis: 
Diagnosed with psychotic 
disorder (schizophrenia or 
schizoaffective disorder): N = 
86 












follow-up of a 
randomised 
controlled trial  
Outcomes:  
(a) Self-reported abstinence 
outcomes over 6 months 
after the intervention: 
number who tried to 
quit, number of quit 
attempts, attained >1 
day abstinence, days of 
abstinence and attained 
>7 days abstinence 
(b) Stage of Change 
 
N = 74 reported quitting 
smoking for at least 1 day 
over the six-month follow-
up period. Average length 
of self-reported abstinence 
among quitters was 18 
days. N = 36 sustained 
abstinence for at least 7 
days. N = 9 persisted in 
their abstinence and 
provided a breath 
CO<10ppm at 6-month 
follow-up.  
Participants’ stage of 
change after intervention 
significantly predicted 
abstinence (alongside level 
of education and smoking 
cessation treatment). When 
both treatment use and 
stage of change after the 
intervention were included 
in the model, only 
treatment use significantly 
predicted abstinence.  
There was no 
comparison group to 
document the rate of 
treatment initiation 
and abstinence in 
people who did not 
receive the website 
 
The self-reported rate 






required: 22)  
 










Intervention: Decision support system to motivate people with SMI to quit smoking [Let’s Talk About Smoking] (Brunette et al., 2017) 
N = 81 (control group = 23, intervention group = 
30, intervention group computerised American 
National Cancer Institute Education = 28) 
Control group (11 female) 
Ethnicity: 
White: N = 20 
Black: N = 2 
Hispanic: N = 5 
Diagnosis: 
Schizophrenia/affective disorders: N = 9 
Mood/anxiety disorders: N = 14 
Intervention group (10 female) 
Ethnicity: 
White: N = 17; Black: N = 9; Hispanic: N = 6;                                   
Other: N = 4 
Diagnosis: 
Schizophrenia/affective: N = 12 
Diagnosis mood/anxiety: N = 18   
Intervention group - Computerised National 
Cancer Institute Education – (9 female) 
Ethnicity: 
White: N = 16; Black: N = 10; Hispanic: N = 0;                                
Other: N = 2 
Diagnosis: Schizophrenia/affective: N = 14 









past 3-month use of 
verifiable cessation 
treatment and quit 
attempts           





attempts with days of 
abstinence, and 
biologically verified 
abstinence at study 
follow-up visits 
Primary outcome: 6% of 
participants who received an 
intervention utilised verifiable 
cessation treatment over the 3-
month follow-up period. 13.9% of 
participants used any type of 
nicotine replacement therapy, 6.9% 
reported talking to a doctor about 
quitting, 6.9% reported talking to a 
counsellor, and 22.2% reported 
talking to a friend.  
 
Secondary outcome: Those who 
received the website were more 
likely to have biologically verified 
abstinence from smoking and other 
tobacco product use than those who 
received the computerised National 
Cancer Institute education 
Small 


















Table 2. Development Studies 














Intervention 1: Decision aid for disclosure of mental illness to employers entitled CORAL (Conceal Or ReveAL) (Brunette et al., 2013) 
Aim: To assist people with mental health problems in reaching decisions regarding disclosure in the employment context (UK) 
Mode of delivery: Pamphlet (A4/12 pages) 
Diagnosis: Bipolar, schizophrenia, other  




N = 8  
Black African: 
N = 3  
Black 
Caribbean: N = 
2 
Black British: 
N = 1  
Other white: N 
= 1 
Diagnosis: 
Bipolar: N = 7  
Schizophrenia: 
N = 1 
Do not know: 
N = 2  
Secondary 
care 
• Systematic review was 
used to inform the 
components of the tool 
 
• Participants with mental 
health condition read 
and completed the draft 
tool and rated it for 




interview data provided 
further feedback which 
was used to amend the 
tool 
 
• Readability of the tool 
was tested and adapted 
following feedback 
from participants 
Six sections:  
(a) ‘Pros and cons’ of 
disclosure 
(b) my disclosure needs 
(c) my disclosure values 
(d) when to tell 
(e) who to tell  
(f) making a decision 
 
Quotes from interviews 
supported sections 
 
The tool was designed to be 
used independently from, 






(Ajzen, 1991)  




































Intervention 2: Decision support system to motivate people with SMI to quit smoking entitled Let’s Talk About Smoking (Brunette et al., 2017; Ferron et al., 2011; 
Ferron et al., 2012) 
Aim: Designed to stimulate motivation in people with SMI to quit smoking by using evidence-based treatment (United States) 
Mode of delivery: web-based 
Diagnosis: Severe mental illness (defined as mood or psychotic disorder with persisting functional disability) 
N = 89 
participants 
referred to the 
study by their 
clinicians.  
80% agreed to 
participate. 
Out of the 
remaining 
20%:  




N = 7 did not 
want to 
participate  
N = 4 did not 
attend the 
research visit 
N = 2 lacked 
the ability to 
read at a 5th 
grade level 





N = 49  
African 
American:  
N = 22  
Secondary 
care 
• Literature review informed 
website development 
• Think aloud method used to 
evaluate the design and layout 
of the website: 
(1) each section of website was 
evaluated, then modified 
following feedback from 
participants  
(2) the whole site was 
evaluated by participants, 
then modified according to 
feedback (N = 8) 
• At the end of the programme, 
the interviewer asked open-
ended questions related to the 
usability and likeability of the 
website; this was followed by a 
debriefing 
• Readability of the tool was 
tested and adapted following 
feedback from participants 
Stage 1: increase 
motivation by 
psychoeducation 
re personal impact 
of smoking 
 




text about quitting 









the content  
 
 







SMI may have 




























































Intervention 3: Patient decision aid for affective disorders (Liebherz et al., 2015) 
Aim: To encourage patients to participate in decision making about their treatment by providing information about the pros and cons of evidence-based treatment options 
Mode of delivery: web-based [www.psychenet.de] (Germany) 
Diagnosis: Bipolar disorder 
N = 930 
participant






survey.    
 
Of these N 









Germany:         
N = 193 
 
Diagnosis: 




• Treatment decisions identified 
through a systematic literature 
search and evidence-based 
treatment options  
• Patients with bipolar disorder 
were involved in the 
development of the informed 
choice tool. Their information 
and decision-making needs 
were explored using an online 
cross-sectional survey – the 
data were used to tailor the 
various components of the 
informed choice tool 
• Self-administered ques-
tionnaire included items on 
their internet use (3 items), 
online health information needs 
(2 items), their role in decision 
making (2 items) and important 
treatment decisions (16 items) 
Three categories of 
information needs 
















high number of 
women in sample 





































Intervention 4: Decision-aid for patients with bipolar II disorder and their families making decisions about treatment options to prevent relapse (Fisher et al., 2018) 
Aim: To facilitate more informed and active patient (and family) involvement in BPII treatment decision-making (Australia) 
Mode of delivery: Booklet (A5/100 pages) 
Diagnosis: Bipolar II disorder  
N/A n = 31 patients 
(24 female) 








n = 25 patients 




















• Informed by the 
International Patient 
Decision-Aid Standards and 
the Ottawa Decision-
Support Framework 
Content, formatting and design were 
based on:  
• a systematic review 
• best available evidence (e.g. 
clinical guidelines, 
published RCTs and meta-
analyses) 
• in-depth qualitative 
interviews with patients, 
family members and 
clinicians 
• iterative review by an expert 
working party 
• health literacy review using 
the Patient Education 
Materials Assessment Tool 
Information was divided into 
three main sections:  
• Medication Options 
• Psychological Options  
• Making Decisions 
 
The DA provides evidence-
based, lay information using 
text and graphics on the 
known efficacy and 
benefits/costs of the current 
first-line medications and 
evidence-supported 
psychological treatments for 
relapse prevention in bipolar 
II disorder.  
Values clarification exercises 
help patients/family consider 
their preferences and 
deliberate on the 
benefits/costs of the different 
treatment options. 
none  Small sample 
































Figure 1. PRISMA Flow Diagram  
 
